Characteristics | TB-IRIS (45) | Non-TB-IRIS (154) | Total (199) | Crude ORb | P value | Adjusted ORc | P value |
---|---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | (95% CI) | (95% CI) | |||
Gender | |||||||
Male | 42 (93.3) | 146 (94.8) | 188 (94.5) | 1 | Ref. | ||
Female | 3 (6.7) | 8 (5.2) | 11 (5.5) | 1.304 (0.331–5.133) | 0.705 | ||
Age group (years) | |||||||
< 25 | 9 (20.0) | 16 (10.4) | 25 (12.6) | 1.744 (0.699–4.351) | 0.233 | 2.024 (0.786–5.212) | 0.144 |
25–44 | 30 (66.7) | 93 (60.4) | 123 (61.8) | 1 | Ref. | 1 | Ref. |
45–64 | 5 (11.1) | 42 (27.3) | 47 (23.6) | 0.369 (0.134–1.018) | 0.054 | 0.355 (0.127–0.993) | 0.049 |
> 64 | 1 (2.2) | 3 (1.9) | 4 (2.0) | 1.033 (0.104–10.310) | 0.978 | 1.603 (0.156–16.479) | 0.692 |
Initial CD4 cell count (cells/mm3) | |||||||
> 100 | 2 (4.4) | 24 (15.6) | 26 (13.1) | 1 | Ref. | ||
50–100 | 3 (6.7) | 25 (16.2) | 28 (14.1) | 1.440 (0.221–9.388) | 0.703 | ||
< 50 | 40 (88.9) | 105 (68.2) | 145 (72.9) | 4.571 (1.033–20.238) | 0.045 | ||
CD4 cell count after ART (cells/mm3) | |||||||
> 100 | 21 (46.7) | 71 (46.1) | 92 (46.2) | 1 | Ref. | ||
50–100 | 16 (35.6) | 42 (27.3) | 58 (29.1) | 1.288 (0.606–2.738) | 0.511 | ||
< 50 | 8 (17.8) | 41 (26.6) | 49 (24.6) | 0.660 (0.268–1.623) | 0.365 | ||
Increase in CD4 cell count | |||||||
< 4 folds | 21 (46.7) | 103 (66.9) | 124 (62.3) | 1 | Ref. | 1 | Ref. |
≥ 4 folds | 24 (53.3) | 51 (33.1) | 75 (37.7) | 2.308 (1.175–4.533) | 0.015 | 2.614 (1.288–5.303) | 0.008 |
HIV virial load (copies/mL) | |||||||
≤ 1000 copies | 24 (53.3) | 94 (61.0) | 118 (59.3) | 1 | Ref. | ||
> 1000 copies | 21 (46.7) | 60 (39.0) | 81 (40.7) | 1.371 (0.702–2.677) | 0.356 | ||
HAART regimena | |||||||
First-line | 38 (84.4) | 136 (88.3) | 174 (87.4) | 1 | Ref. | ||
Second-line | 7 (15.6) | 18 (11.7) | 25 (12.6) | 1.392 (0.541–3.578) | 0.493 |